GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Secondary Objectives: * To evaluate the objective response rate to PRV combination therapy in patients with previously untreated MCL. * To evaluate the duration of response in patients with an objective response to PRV combination therapy. * To evaluate the progression-free survival and overall survival in patients treated with PRV combination therapy. * To evaluate the safety profile of PRV combination therapy in patients with previously untreated MCL.